MEGESTROL ACETATE Drug Patent Profile
✉ Email this page to a colleague
When do Megestrol Acetate patents expire, and what generic alternatives are available?
Megestrol Acetate is a drug marketed by Chartwell, Hikma, Novitium Pharma, Strides Pharma, Teva Pharms, Twi Pharms, Xttrium Labs Inc, Barr, Teva, and Usl Pharma. and is included in fifteen NDAs.
The generic ingredient in MEGESTROL ACETATE is megestrol acetate. There are eighteen drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Megestrol Acetate
A generic version of MEGESTROL ACETATE was approved as megestrol acetate by STRIDES PHARMA on August 8th, 1988.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MEGESTROL ACETATE?
- What are the global sales for MEGESTROL ACETATE?
- What is Average Wholesale Price for MEGESTROL ACETATE?
Summary for MEGESTROL ACETATE
| US Patents: | 0 |
| Applicants: | 10 |
| NDAs: | 15 |
| Finished Product Suppliers / Packagers: | 16 |
| Raw Ingredient (Bulk) Api Vendors: | 90 |
| Clinical Trials: | 73 |
| Patent Applications: | 3,536 |
| Drug Prices: | Drug price information for MEGESTROL ACETATE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MEGESTROL ACETATE |
| What excipients (inactive ingredients) are in MEGESTROL ACETATE? | MEGESTROL ACETATE excipients list |
| DailyMed Link: | MEGESTROL ACETATE at DailyMed |
Recent Clinical Trials for MEGESTROL ACETATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 1/Phase 2 |
| Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Phase 2 |
| Ontario Institute for Cancer Research | Phase 1 |
Pharmacology for MEGESTROL ACETATE
| Drug Class | Progestin |
Medical Subject Heading (MeSH) Categories for MEGESTROL ACETATE
Anatomical Therapeutic Chemical (ATC) Classes for MEGESTROL ACETATE
Paragraph IV (Patent) Challenges for MEGESTROL ACETATE
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MEGACE ES | Oral Suspension | megestrol acetate | 125 mg/mL | 021778 | 1 | 2011-04-27 |
US Patents and Regulatory Information for MEGESTROL ACETATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartwell | MEGESTROL ACETATE | megestrol acetate | SUSPENSION;ORAL | 204688-001 | Dec 1, 2017 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Twi Pharms | MEGESTROL ACETATE | megestrol acetate | SUSPENSION;ORAL | 203139-001 | Aug 27, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Novitium Pharma | MEGESTROL ACETATE | megestrol acetate | SUSPENSION;ORAL | 077404-001 | Feb 16, 2006 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
